Study Shows Zero Stent Fractures For Supera® In Popliteal Artery

IDEV Technologies is trumpeting results from a newly published study which suggest that its Supera stent could be a treatment option for patients that would not have been offered a standard nitinol stent for popliteal artery disease.



Twelve-Month Outcomes of Popliteal Artery Treatment with the Supera® Peripheral Stent System Published in JACC Cardiovascular Interventions (via PR Newswire)

— Data includes Primary Patency Rate of 87.7% at 12 Months and Zero Stent Fractures — WEBSTER, Texas, Feb. 5, 2013 /PRNewswire/ — IDEV Technologies today announced the publication of positive clinical outcomes for the Supera® Peripheral Stent System in the Journal of American College of Cardiology…


published: February 5, 2013 in: Clinical Studies/Trials, Vascular

Most read

Latest

^